Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway

Ramy F. Youssef, Nicholas G. Cost, Oussama M. Darwish, Vitaly Margulis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.

Original languageEnglish (US)
Pages (from-to)110-117
Number of pages8
JournalArab Journal of Urology
Volume10
Issue number2
DOIs
StatePublished - Jun 2012

Fingerprint

Sirolimus
Renal Cell Carcinoma
Carcinogenesis
PubMed
Libraries
Neoplasms

Keywords

  • Molecular markers
  • mTOR
  • Prognostic
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic markers in renal cell carcinoma : A focus on the 'mammalian target of rapamycin' pathway. / Youssef, Ramy F.; Cost, Nicholas G.; Darwish, Oussama M.; Margulis, Vitaly.

In: Arab Journal of Urology, Vol. 10, No. 2, 06.2012, p. 110-117.

Research output: Contribution to journalArticle

Youssef, Ramy F. ; Cost, Nicholas G. ; Darwish, Oussama M. ; Margulis, Vitaly. / Prognostic markers in renal cell carcinoma : A focus on the 'mammalian target of rapamycin' pathway. In: Arab Journal of Urology. 2012 ; Vol. 10, No. 2. pp. 110-117.
@article{1e1c631afdc4428b866b3595e3f73434,
title = "Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway",
abstract = "Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.",
keywords = "Molecular markers, mTOR, Prognostic, Renal cell carcinoma",
author = "Youssef, {Ramy F.} and Cost, {Nicholas G.} and Darwish, {Oussama M.} and Vitaly Margulis",
year = "2012",
month = "6",
doi = "10.1016/j.aju.2012.02.005",
language = "English (US)",
volume = "10",
pages = "110--117",
journal = "Arab Journal of Urology",
issn = "2090-598X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Prognostic markers in renal cell carcinoma

T2 - A focus on the 'mammalian target of rapamycin' pathway

AU - Youssef, Ramy F.

AU - Cost, Nicholas G.

AU - Darwish, Oussama M.

AU - Margulis, Vitaly

PY - 2012/6

Y1 - 2012/6

N2 - Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.

AB - Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.

KW - Molecular markers

KW - mTOR

KW - Prognostic

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84864440385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864440385&partnerID=8YFLogxK

U2 - 10.1016/j.aju.2012.02.005

DO - 10.1016/j.aju.2012.02.005

M3 - Article

C2 - 26558012

AN - SCOPUS:84864440385

VL - 10

SP - 110

EP - 117

JO - Arab Journal of Urology

JF - Arab Journal of Urology

SN - 2090-598X

IS - 2

ER -